IP Library Granted Patent US 10,966,987
Granted Patent B2
US 10,966,987 · App. 16/522,550 · Granted Apr 6, 2021

Therapeutic compounds and uses thereof

Inventors: Winston Zapanta Ong (Watertown, MA); Pawel Wojciech Nowak (Watertown, MA); Ben C. Askew (Watertown, MA); Jinsoo Kim (Watertown, MA)
Assignee: Kala Pharmaceuticals, Inc.
A61K31/5377A61K9/0048A61K9/10A61K9/146A61K31/4709A61K31/505A61K31/506C07D239/88C07D405/12C07D413/14C07D491/107Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,966,987
App. No.
16/522,550
Granted
Apr 6, 2021
Kind
B2
Abstract

Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.

Claims (51)

1. A compound, having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is hydrogen, substituted C 1-6 alkyl, or unsubstituted C 1-6 alkyl;

R 2 is hydrogen, substituted carbocyclyl, unsubstituted carbocyclyl, substituted heterocyclyl, unsubstituted heterocyclyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl;

X is a bond, —O—, —S—, —NR A1 —, —C(═))—, branched substituted C 1-6 alkylene, unbranched substituted C 1-6 alkylene, branched unsubstituted C 1-6 alkylene, or unbranched unsubstituted C 1-6 alkylene;

R A1 is hydrogen, substituted acyl, unsubstituted acyl, substituted alkyl, unsubstituted alkyl, or a nitrogen protecting group;

Y is N or CH;

each occurrence of R 3 is, independently, hydrogen, halogen, substituted acyl, unsubstituted acyl, substituted alkyl, unsubstituted alkyl, substituted alkenyl, unsubstituted alkenyl, substituted alkynyl, unsubstituted alkynyl, substituted carbocyclyl, unsubstituted carbocyclyl, substituted heterocyclyl, unsubstituted heterocyclyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, —CN, —NO 2 , —OR D1a , —N(R D1a ) 2 , —SR D1a , —CH 2 OR D1a , —CH 2 N(R D1a ) 2 , CH 2 SR D1a , —C(═O)R D1a , —C(═O)OR D1a , —C(═O)SR D1a , —C(═O)N(R D1a ) 2 , —C(═S)R D1a , —C(═S)OR D1a , —C(═O)R D1a , —(═O)OR D1a , —C(═NR D1a )R D1a , —C(═NR D1a )OR D1a , —C(═NR D1a )SR D1a , or C(═CR D1a )N(R D1a ) 2 ;

each occurrence of R D1a is, independently, hydrogen, substituted alkyl, unsubstituted alkyl, substituted alkenyl, unsubstituted alkenyl, substituted alkynyl, unsubstituted alkynyl, substituted carbocyclyl, unsubstituted carbocyclyl, substituted heterocyclyl, unsubstituted heterocyclyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl, or two R D1a groups are joined to form a substituted heterocyclic ring or an unsubstituted heterocyclic ring;

Z is substituted aliphatic, unsubstituted aliphatic, substituted heterocyclyl, unsubstituted heterocyclyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted heterocyclylalkyl, unsubstituted heterocyclylalkyl, substituted arylalkyl, unsubstituted arylalkyl, substituted heteroaralkyl, unsubstituted heteroaralkyl, substituted quinolyl, or unsubstituted quinolyl;

m is 0, 1, 2, 3, or 4; and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

2. The compound of claim 1 , wherein:

R 1 is hydrogen, substituted C 1-6 alkyl, or unsubstituted C 1-6 alkyl;

R 2 is heterocyclyl;

X is a bond, —O—, or —C(═O)—;

each occurrence of R 3 is, independently, hydrogen, F, Cl, Br, I, CN, or OH;

Y is CH or N;

Z is substituted aliphatic, unsubstituted aliphatic, substituted heterocyclylalkyl, unsubstituted heterocyclylalkyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted quinolyl, or unsubstituted quinolyl;

m is 0, 1, 2, 3, or 4; and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

3. The compound of claim 1 , wherein:

R 1 is hydrogen, substituted C 1-6 alkyl, or unsubstituted C 1-6 alkyl;

R 2 is heterocyclyl;

X is a bond, —O—, or —C(═O)—;

each occurrence of R 3 is, independently, hydrogen, F, Cl, Br, I, CN, or OH;

Y is CH;

Z is C 1-6 alkyl, substituted heterocyclylalkyl, unsubstituted heterocyclylalkyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted quinolyl, or unsubstituted quinolyl;

m is 0, 1, 2, 3, or 4; and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

4. The compound of claim 1 , wherein R 2 is

5. The compound of claim 1 , wherein R 2 is

6. The compound of claim 1 , having a formula:

or a pharmaceutically acceptable salt thereof.

7. A composition, comprising the compound of claim 1 .

8. A composition, comprising the compound of claim 2 .

9. A composition, comprising the compound of claim 3 .

10. A composition, comprising the compound of claim 4 .

11. A composition, comprising the compound of claim 5 .

12. A composition, comprising the compound of claim 6 .

13. A pharmaceutical composition, comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition, comprising the compound of claim 2 and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition, comprising the compound of claim 3 and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition, comprising the compound of claim 4 and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition, comprising the compound of claim 5 and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition, comprising the compound of claim 6 and a pharmaceutically acceptable carrier.

19. The compound of claim 1 , having a formula:

or a pharmaceutically acceptable salt thereof.

20. A composition, comprising the compound of claim 19 .

21. A pharmaceutical composition, comprising the compound of claim 19 and a pharmaceutically acceptable carrier.

Assignments (6)
CHANGE OF NAME Recorded Sep 21, 2023
From: KALA PHARMACEUTICALS, INC.
To: KALA BIO, INC.
Reel/Frame 065017/0488 →
FIRST AMENDMENT TO IP SECURITY AGREEMENT Recorded Dec 22, 2022
From: KALA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 062205/0883 →
SECURITY INTEREST Recorded May 6, 2021
From: KALA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 056168/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2019
From: ONG, WINSTON Z.; NOWAK, PAWEL W.; KIM, JINSOO
To: KALA PHARMACEUTICALS, INC.
Reel/Frame 049873/0997 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2019
From: ASKEW, BEN C.
To: BREAKTHROUGH CHEMISTRY ADVISORS, LLC
Reel/Frame 049874/0088 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2019
From: BREAKTHROUGH CHEMISTRY ADVISORS, LLC
To: KALA PHARMACEUTICALS, INC.
Reel/Frame 049874/0182 →
Continuity (6)
Continuation 15868894 · Jan 11, 2018
Continuation 15139107 · Apr 26, 2016
Division 14181095 · Feb 14, 2014
Provisional Application 61898778 · Nov 1, 2013
Provisional Application 61765487 · Feb 15, 2013
Related Publication 20200054644A1 · Feb 20, 2020